Abstract
Nanomedicine clearly offers unique tools to address intractable medical problems in cancer and cardiovascular disease from entirely new perspectives. Among the theranostic options emerging in this new wave of biotechnology development, the perfluorocarbon nanoparticles have shown robust potential in vivo for diagnosing, characterizing, treating and following proliferating cancers, progressive atherosclerosis, rheumatoid arthritis and much more. These molecular imaging agents have been demonstrated for use with ultrasound, MRI, CT, and SPECT/CT. Moreover, the synergism of imaging for confirmation of therapeutic delivery, for dosimetry, and for noninvasively following early treatment responses is discussed. Image-guided drug delivery based on nanotechnology is emerging as a powerful clinical opportunity, and PFC nanoparticles are among the leading technologies reaching clinical testing today with this potential.
| Original language | English (US) |
|---|---|
| Title of host publication | Nanopharmaceutics |
| Subtitle of host publication | The Potential Application of Nanomaterials |
| Publisher | World Scientific Publishing Co. |
| Pages | 293-346 |
| Number of pages | 54 |
| ISBN (Electronic) | 9789814368674 |
| ISBN (Print) | 9789814368667 |
| DOIs | |
| State | Published - Jan 1 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- General Biochemistry, Genetics and Molecular Biology
- General Engineering
- General Medicine
- General Health Professions
Fingerprint
Dive into the research topics of 'Perfluorocarbon nanoparticles: A theranostic platform technology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver